Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcium aluminium silicate - Salient Pharmaceuticals

Drug Profile

Calcium aluminium silicate - Salient Pharmaceuticals

Alternative Names: Aluminium calcium silicate; Aluminum calcium silicate; Calcium alumina-silicate; Calcium aluminosilicate; Calcium aluminosilicate anti-diarrheal; Calcium aluminosilicate anti-diarrhoeal - Salient Pharmaceuticals; Calcium aluminum silicate; Calcium silicoaluminate; CASAD; Silicate cement; Silicic acid aluminium calcium salt; Silicic acid aluminum calcium salt

Latest Information Update: 19 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Salient Pharmaceuticals
  • Developer Salient Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Aluminium compounds; Antidiarrhoeals; Calcium compounds; Noncarboxylic acids
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Clostridium difficile infections; Diarrhoea; Inflammatory bowel diseases; Proctitis; Stomatitis

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Phase-II for Diarrhoea (Chemotherapy-induced) in USA (PO)
  • 19 Apr 2016 No recent reports on development identified - Preclinical for Clostridium difficile infections in USA (PO)
  • 19 Apr 2016 No recent reports on development identified - Preclinical for Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top